Abstract: The invention relates to ?-L-N4-hydroxycytosine nucleo-sides, pharmaceutical agents comprising same, and to the use of said ?-L-N4-hydroxycytosine nucleosides and pharmaceutical agents in the prophylaxis or therapy of an infection caused by hepatitis B virus (HBV) or human immunodeficiency virus (HIV). The invention also relates to a method for the preparation of said ?-L-nucleoside analogs.

Abstract: Nucleoside analogs, nucleic acids and pharmaceutical agents comprising same, and to the use of said nucleoside analogs, nucleic acids and pharmaceutical agents in the diagnosis, prophylaxis or therapy of a viral, bacterial, fungicidal and/or parasitic infection, or of cancer, particularly of hepatitis infections. The invention also relates to a method for the preparation of said nucleoside analogs and to a kit and the use thereof in the prophylaxis and therapy of viral diseases, particularly of hepatitis infections. As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims.

Abstract: The invention relates to novel chimeric oligonucleotides and their use, especially to bind and inhibit the enzyme telomerase. The oligonucleotides were prepared in view of RNA's non-binding activity to phosphorothioates and the primer binding site of the enzyme. The oligonucleotides bind to the primer binding site thereby resulting in maximum inhibition of the enzyme.

Abstract: 2',3'-dideoxynucleoside pyrimidine compounds and 2-thiothymidine carbocyclic derivatives with antiviral activity are disclosed. These compounds are expected to exhibit antiviral activity recognized for 2',3'-dideoxynucleoside compounds and analogs thereof.

Abstract: A process for treating AIDS, which comprises administering to a patient in need therefor a pharmaceutical composition comprising a therapeutically effective amount of a compound having the formula ##STR1## wherein: R.sub.1 is an adenine, cytosine, guanine, thymidine, uracil, 5-substituted uracil, 5-substituted cytosine derivative, 2-fluoroadenine, 2.6-diaminopurine, 2-aminopurine, 6-thioguanine, or 7-deazaadenine group;R.sub.2 is H, or a OH group;R.sub.3 is a OH, O-acyl, O-palmitoyl group or phosphates (as free acid, or its alkali, ammonium or alkyl ammonium salts), or any other precursor group for the hydroxyl group;or a physiologically acceptable salt thereof.

Abstract: A method for treating AIDS, which comprises administering to a patient in need therefor a pharmaceutical composition comprising a therapeutically effective amount of a compound having the formula ##STR1## wherein R.sub.1 is an adenine, cytosine, guanine, thymidine, uracil, 5-substituted uracil, 5-substituted cytosine derivative, 2-fluoroadenine, 2.6-diaminopurine, 2-aminopurine, 6-thioguanine, or 7-deazaadenine group;R.sub.2 is H, or a OH group;R.sub.3 is a OH, O-acyl, O-palmitoyl group, or phosphates (as free acid, or its alkali, ammonium or alkyl ammonium salts), or any other precursor group for the hydroxyl group;or a physiologically acceptable salt thereof.

Abstract: The invention relates to novel glycero-3(2)phospho-L-serine derivatives of the general formula ##STR1## in which A represents unsubstituted or substituted (C5-C30) alkoxy, or unsubstituted or substituted (C5-C30) alkenoxy, whereby a double bond of the alkenoxy residue does not originate at the C atom bound to oxygen, or halogen, or a group of the general formula--O--(CH.sub.2).sub.n --CF.sub.3 II,wherein n is 0 or an integer 1, 2 or 3, one of the two residues B and C, which is identical to or different from A, has one of the definitions given for A or represents hydrogen, and the respective other residue represents the phosphatidyl-Lserine group of the formula ##STR2## with the proviso that at least one residue A, B or C represents (C5-C30) alkoxy or (C5-C30) alkenoxy; and the pharmaceutically acceptable salts of compounds of general formula I with bases, a process for the preparation thereof, pharmaceutical preparations containing the said compounds, and their use in drugs with cytostatic activity.